Press Releases

Date	Title
Toggle SummaryMar 30, 2015	Kura Oncology’s Menin-Mll Inhibitor Program Shows Promise In Study Published In Cancer Cell; Program Targeting Acute Leukemias Licensed From University Of Michigan LA JOLLA, March 30, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced a study published by University of Michigan researchers in the
Toggle SummaryMar 12, 2015	Kura Oncology Announces License Agreement with Janssen Pharmaceutica for Development and Commercialization of Tipifarnib; Closes $60 Million Private Placement and Completes Reverse Merger LA JOLLA, March 12, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced several milestones.

Mar 30, 2015

Kura Oncology’s Menin-Mll Inhibitor Program Shows Promise In Study Published In Cancer Cell; Program Targeting Acute Leukemias Licensed From University Of Michigan

LA JOLLA, March 30, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced a study published by University of Michigan researchers in the

Mar 12, 2015

Kura Oncology Announces License Agreement with Janssen Pharmaceutica for Development and Commercialization of Tipifarnib; Closes $60 Million Private Placement and Completes Reverse Merger

LA JOLLA, March 12, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced several milestones.

Tools

Press Releases